ArticleCureus2025
An Effective Outcome Despite Delayed Treatment Initiation in a Female With Kallmann Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kallmann syndrome (KS) is an idiopathic hypogonadotropic hypogonadism with anosmia due to isolated gonadotropin-releasing hormone deficiency. In females, the diagnosis often occurs around age 15 due to primary amenorrhea, prompting hormone replacement therapy (HRT) initiation. However, limited data exists on the effectiveness of delayed HRT in females with KS. Here, we describe a case involving a female with KS who began treatment at the age of 27. Following HRT initiation, the patient showed increases in uterine size, bone mineral density, and growth of breasts over a two-year period. Delayed diagnosis of KS in females, as in this case, is extremely rare, and this case demonstrates two important clinical issues. First, HRT can still be effective in females with KS even if treatment initiation is delayed, and, second, therapeutic benefits become apparent within two years following initiation of treatment. These findings may be applicable to other patients with congenital hypogonadotropic hypogonadism whose treatment initiation was delayed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.